GlassScriptPhysician profile
Gavin Douglas Chartier
NPI 1982679494
$5,637.19
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $1,876 · 2021: $856 · 2022: $786 · 2023: $407 · 2024: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,201.17 | 2020 | |
| Medtronic, INC. | $749.54 | 2021-2023 | Synchromedii, Intellis Adaptivestim, Vanta Adaptivestim |
| Stimwave Technologies Incorporated | $611.12 | 2019-2022 | |
| Nevro Corp. | $477.90 | 2019-2024 | Senza |
| Vertos Medical, INC. | $303.42 | 2019-2021 | |
| Eisai INC. | $246.98 | 2020-2022 | |
| Lilly USA, LLC | $213.79 | 2019-2022 | |
| Stryker Corporation | $192.75 | 2019 | |
| Medtronic USA, INC. | $176.45 | 2019-2020 | |
| Pfizer INC. | $131.60 | 2019-2023 | |
| Grt US Holding, INC. | $119.00 | 2022 | |
| Amgen INC. | $105.71 | 2020-2021 | |
| Si-Bone, INC. | $100.80 | 2024 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $78.80 | 2021-2024 | Qulipta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $77.22 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $72.02 | 2021 | |
| Boston Scientific Corporation | $69.25 | 2019-2024 | |
| Upsher-Smith Laboratories LLC | $59.14 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.43 | 2019 | |
| Flowonix Medical Incorporated | $52.17 | 2020 | |
| Collegium Pharmaceutical, INC. | $48.69 | 2020-2021 | |
| Mml US, INC. | $48.14 | 2023 | Reactiv8 |
| Merck Sharp & Dohme LLC | $43.47 | 2022-2023 | Belsomra |
| Abbott Laboratories | $42.87 | 2024 | Proclaim |
| Zyla Life Sciences, INC. | $40.42 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.76 | 2022 | |
| Daiichi Sankyo INC. | $31.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.07 | 2020 | |
| Scilex Pharmaceuticals INC. | $21.34 | 2024 | |
| Bioventus LLC | $19.62 | 2022 | |
| Virtus Pharmaceuticals LLC | $16.90 | 2021 | |
| Lundbeck LLC | $14.01 | 2022 | |
| Alkermes, INC. | $13.93 | 2022 | |
| Allergan, INC. | $13.76 | 2020 | |
| Biodelivery Sciences International, INC. | $13.73 | 2020 | |
| Spinal Simplicity, LLC | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Chartier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.